Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.
Ng TW, Furuyama W, Wirchnianski AS, Saavedra-Ávila NA, Johndrow CT, Chandran K, Jacobs WR, Marzi A, Porcelli SA. Ng TW, et al. Among authors: wirchnianski as. bioRxiv [Preprint]. 2024 May 29:2024.05.28.595735. doi: 10.1101/2024.05.28.595735. bioRxiv. 2024. Update in: Front Immunol. 2024 Jul 16;15:1429909. doi: 10.3389/fimmu.2024.1429909 PMID: 38853867 Free PMC article. Updated. Preprint.
Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
Wirchnianski AS, Nyakatura EK, Herbert AS, Kuehne AI, Abbasi SA, Florez C, Storm N, McKay LGA, Dailey L, Kuang E, Abelson DM, Wec AZ, Chakraborti S, Holtsberg FW, Shulenin S, Bornholdt ZA, Aman MJ, Honko AN, Griffiths A, Dye JM, Chandran K, Lai JR. Wirchnianski AS, et al. PLoS Pathog. 2024 Apr 11;20(4):e1012134. doi: 10.1371/journal.ppat.1012134. eCollection 2024 Apr. PLoS Pathog. 2024. PMID: 38603762 Free PMC article.
Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines.
Felgner J, Clarke E, Hernandez-Davies JE, Jan S, Wirchnianski AS, Jain A, Nakajima R, Jasinskas A, Strahsburger E, Chandran K, Bradfute S, Davies DH. Felgner J, et al. Among authors: wirchnianski as. Antiviral Res. 2024 May;225:105851. doi: 10.1016/j.antiviral.2024.105851. Epub 2024 Mar 7. Antiviral Res. 2024. PMID: 38458540 Free article.
Genomic surveillance of SARS-CoV-2 during the first year of the pandemic in the Bronx enabled clinical and epidemiological inference.
Fels JM, Khan S, Forster R, Skalina KA, Sirichand S, Fox AS, Bergman A, Mitchell WB, Wolgast LR, Szymczak WA, Bortz RH 3rd, Dieterle ME, Florez C, Haslwanter D, Jangra RK, Laudermilch E, Wirchnianski AS, Barnhill J, Goldman DL, Khine H, Goldstein DY, Daily JP, Chandran K, Kelly L. Fels JM, et al. Among authors: wirchnianski as. Cold Spring Harb Mol Case Stud. 2022 Jul 13;8(5):a006211. doi: 10.1101/mcs.a006211. Online ahead of print. Cold Spring Harb Mol Case Stud. 2022. PMID: 35831070 Free PMC article.
Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo.
Georgiev GI, Malonis RJ, Wirchnianski AS, Wessel AW, Jung HS, Cahill SM, Nyakatura EK, Vergnolle O, Dowd KA, Cowburn D, Pierson TC, Diamond MS, Lai JR. Georgiev GI, et al. Among authors: wirchnianski as. Cell Chem Biol. 2022 May 19;29(5):811-823.e7. doi: 10.1016/j.chembiol.2022.02.004. Epub 2022 Feb 28. Cell Chem Biol. 2022. PMID: 35231399 Free PMC article.
Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes.
Lasso G, Khan S, Allen SA, Mariano M, Florez C, Orner EP, Quiroz JA, Quevedo G, Massimi A, Hegde A, Wirchnianski AS, Bortz RH 3rd, Malonis RJ, Georgiev GI, Tong K, Herrera NG, Morano NC, Garforth SJ, Malaviya A, Khokhar A, Laudermilch E, Dieterle ME, Fels JM, Haslwanter D, Jangra RK, Barnhill J, Almo SC, Chandran K, Lai JR, Kelly L, Daily JP, Vergnolle O. Lasso G, et al. Among authors: wirchnianski as. PLoS Comput Biol. 2022 Jan 18;18(1):e1009778. doi: 10.1371/journal.pcbi.1009778. eCollection 2022 Jan. PLoS Comput Biol. 2022. PMID: 35041647 Free PMC article.
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group; Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE. Ortigoza MB, et al. JAMA Intern Med. 2022 Feb 1;182(2):115-126. doi: 10.1001/jamainternmed.2021.6850. JAMA Intern Med. 2022. PMID: 34901997 Free PMC article. Clinical Trial.
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D, Dieterle ME, Wec AZ, O'Brien CM, Sakharkar M, Florez C, Tong K, Rappazzo CG, Lasso G, Vergnolle O, Wirchnianski AS, Bortz RH 3rd, Laudermilch E, Fels JM, Mengotto A, Malonis RJ, Georgiev GI, Quiroz JA, Wrapp D, Wang N, Dye KE, Barnhill J, Dye JM, McLellan JS, Daily JP, Lai JR, Herbert AS, Walker LM, Chandran K, Jangra RK. Haslwanter D, et al. Among authors: wirchnianski as. mBio. 2021 Oct 26;12(5):e0247321. doi: 10.1128/mBio.02473-21. Epub 2021 Oct 5. mBio. 2021. PMID: 34607456 Free PMC article.
35 results